Abstract 191P
Background
Gastric cancer (GC) is a major global health concern, with prognosis influenced by tumor stage and its microenvironment, especially immune cell presence. This research investigates the relation between CD8 T cell expression, emphasizing CXCR6, and GC survival outcomes.
Methods
Using TCGA-STAD RNA-seq data, we studied a cohort of 280 Stage 2 and 3 GC patients. CD8 T cell expression was examined through X Cell Analysis, followed by Cutoff Determination via R package Maxstat. Post categorization into CD8L and CD8H groups, Differential Gene Expression Analysis identified 495 upregulated and 102 downregulated genes. Weighted Gene Co-expression Network Analysis highlighted CXCR6's importance. Correlations between CXCR6, immune cell infiltration, and survival patterns were explored. Verification came from GES 62254 data and Immunohistochemical Staining of a sample from Dong-A University Hospital.
Results
The findings reveal that heightened CXCR6 expression is significantly associated with improved survival outcomes in both recurrence-free survival (RFS) and overall survival (OS) using TCGA-STAD data. Importantly, the validation using GES 62254 data consistently supports these results. Moreover, the study delves into the tumor microenvironment using TCGA-STAD RNA-seq data, showcasing a positive link between CXCR6 expression and immune cell presence, particularly CD8 T cells, T cell gamma delta cells, NK cells, and activated DCs. This suggests a potential reinforcement of anti-tumor responses. The research further uncovers correlations between CXCR6 expression and markers of CD8 T cell activation, as well as the activation of DCs.Importantly, a clinical investigation involving GC patients treated at Dong-A University Hospital supports the statistical significance of increased CXCR6 expression in relation to enhanced survival rates.
Conclusions
Our research showcases the relationship between enhanced CXCR6 expression and improved GC patient survival. It presents CXCR6 as a potential prognostic biomarker, underscoring its role in the tumor immune milieu. The focus on CD8 T cells and immune pathways suggests promising therapeutic directions, marking a step toward precision-based GC interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
National foundation of Korea grant.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract